Back to Search
Start Over
Guillain-Barre Syndrome Associated with Peginterferon Alfa-2a: A Case Report
- Source :
- Türkiye Fiziksel Tip ve Rehabilitasyon Dergisi. 60:65-68
- Publication Year :
- 2014
- Publisher :
- Baycinar Tibbi Yayincilik, 2014.
-
Abstract
- Polyethylene glycol-interferon α (PEG-IFNα), used in the treatment of chronic hepatitis C, has the potential risk for serious side effects. Among the most frequent side effects are symptoms similar to flu, depression, nervousness, and bone marrow suppression. Serious neurological side effects that have an influence on the peripheral nerves are rarely reported. In this article, a 58-year-old woman with the clinical findings of Guillain-Barre syndrome in the sixth week of PEG-IFa-2a treatment is analyzed and discussed.
- Subjects :
- medicine.medical_specialty
Guillain-Barre syndrome
business.industry
Potential risk
Rehabilitation
Physical Therapy, Sports Therapy and Rehabilitation
medicine.disease
Surgery
Peripheral
Chronic hepatitis
Bone marrow suppression
Internal medicine
medicine
business
Depression (differential diagnoses)
Peginterferon alfa-2a
medicine.drug
Subjects
Details
- ISSN :
- 13086316 and 13020234
- Volume :
- 60
- Database :
- OpenAIRE
- Journal :
- Türkiye Fiziksel Tip ve Rehabilitasyon Dergisi
- Accession number :
- edsair.doi...........47f928d5a2c35ecc316c3b5b798c8876